Shen Hsiao-Chin, Tseng Che-Hao, Lin Yi-Hsuan, Yeh Hsiao-Yun, Tsai Hung-Cheng, Hong Shiao-Ya, Li Tzu-Hao, Su Chien-Wei, Perng Diahn-Warng, Yang Ying-Ying, Hou Ming-Chih
Department of Medical Education, Taipei Veterans General Hospital, Taipei, Taiwan.
Department of Chest, Taipei Veterans General Hospital, Taipei, Taiwan.
Ther Adv Respir Dis. 2025 Jan-Dec;19:17534666251320875. doi: 10.1177/17534666251320875.
Pulmonary function tests offer crucial parameters for evaluating lung health and predicting clinical outcomes. Hyperlipidemia, a prevalent metabolic disorder, has been linked to declining pulmonary function. Statins are an essential therapy for lowering lipid levels in hyperlipidemia.
This study aims to investigate the therapeutic potential of statins in mitigating the decline in pulmonary function.
This is a retrospective cohort study.
Out of 8286 patients who underwent spirometry testing from January 2018 to December 2020, 492 patients were included in the final analysis. The relationship between statin usage, dosage, along with other biometric indices and spirometry parameters were evaluated. Multivariate logistic regression analyses were employed to assess the association between statin use and the decline in pulmonary function.
In patients with persistent hyperlipidemia, the use of statins was associated with a higher predicted percentage of forced expiratory volume in 1 second (FEV1) compared to non-users (84.0% vs 78.0%, = 0.015). Logistic regression models further revealed that statin use independently prevented FEV1 decline, irrespective of dosage (adjusted OR 0.036, 95% CI: 0.002-0.618 in lower statins dose group and adjusted OR 0.170, 95% CI: 0.019-1.552 in higher statins dose group).
The findings suggested that statin usage, regardless of dosage, independently mitigated the decline in pulmonary function among patients with persistent hyperlipidemia. Early initiation of statin therapy may hold promise for individuals experiencing hyperlipidemia and declining pulmonary function.
肺功能测试为评估肺部健康和预测临床结果提供了关键参数。高脂血症是一种常见的代谢紊乱疾病，与肺功能下降有关。他汀类药物是降低高脂血症患者血脂水平的重要治疗药物。
本研究旨在探讨他汀类药物在减轻肺功能下降方面的治疗潜力。
这是一项回顾性队列研究。
在2018年1月至2020年12月接受肺活量测定的8286例患者中，492例患者纳入最终分析。评估他汀类药物的使用、剂量以及其他生物特征指标与肺活量测定参数之间的关系。采用多因素逻辑回归分析评估他汀类药物使用与肺功能下降之间的关联。
在持续性高脂血症患者中，使用他汀类药物的患者1秒用力呼气量（FEV1）的预测百分比高于未使用者（84.0%对78.0%，P = 0.015）。逻辑回归模型进一步显示，无论剂量如何，使用他汀类药物均可独立预防FEV1下降（低剂量他汀类药物组调整后的比值比为0.036，95%置信区间：0.002 - 0.618；高剂量他汀类药物组调整后的比值比为0.170，95%置信区间：0.019 - 1.552）。
研究结果表明，无论剂量大小，他汀类药物的使用均可独立减轻持续性高脂血症患者的肺功能下降。对于患有高脂血症且肺功能下降的个体，早期启动他汀类药物治疗可能具有前景。
